Cancer's greatest defense has always been its capacity to change — to scatter its vulnerabilities across a mosaic of cells no single drug can fully reach. Researchers at Washington University School of Medicine have answered this with a form of molecular improvisation: using click chemistry to assemble existing, FDA-approved antibodies and drug conjugates inside the body itself, forming combinations tailored to the particular face a tumor is wearing. Published in Nature, the work suggests that the future of precision oncology may lie not in endlessly engineering new drugs, but in learning to r